Moderna Inc. (NASDAQ:MRNA) investors spent months treating the company’s cancer vaccine as a potential cure. Last week, leaked trial data delivered a reality check. The stock plunged roughly 26% intra[...]
By using this site, you agree to the storage of cookies on your device for enhanced navigation, site analysis, and The TradingPub's marketing. Data sharing with social media platforms might occur based on the privacy choices you make on those platforms. For specifics, see our Privacy Policy.